The histidine-rich calcium binding protein (HRC) promotes tumor metastasis in hepatocellular carcinoma and is upregulated by SATB1
Metrics: PDF 1805 views | HTML 1788 views | ?
Jingmei Liu1, Ping Han1, Mengke Li1, Wei Yan1, Jin Liu1, Jiqiao Liu2, Jiayi He1, Wei Tu1, Yujia Xia1, Zhenzhen Zhou1, Jin Gong1, Mei Liu1, Qiang Ding1, Dean Tian1
1Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
2Department of Medical Ultrasound, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
Dean Tian, e-mail: email@example.com
Keywords: HRC, Focal Adhesion Turnover, SATB1, Hepatocellular carcinoma, Metastasis
Received: November 03, 2014 Accepted: January 07, 2015 Published: January 22, 2015
The histidine-rich calcium binding protein (HRC) is a regulator of Ca2+-homeostasis. Herein, we found that HRC was frequently upregulated in human hepatocellular carcinoma (HCC) tissues, and its expression was correlated with tumor size and metastasis. Moreover, HRC expression was positively related to the metastatic potential of HCC cell lines. Knockdown of HRC suppressed cell invasion and migration in vitro, whereas ectopic expression of HRC resulted in increased cell invasion and migration in vitro and intrahepatic and lung metastasis in vivo. Interestingly, the pro-invasion and pro-migration effects of HRC were associated with focal adhesion turnover, which was a consequence of FAK phosphorylation. Further experiments showed that HRC induced phospho-FAK, focal adhesion turnover and cell migration through Ca2+/CaM singaling. We found that HRC increased [Ca2+]i by inhibiting the expression of SERCA2. In addition, upregulation of HRC in HCC was attributed to SATB1, which is known to promote HCC metastasis. Ectopic expression of SATB1 enhanced HRC gene transcription by activating AP-1 in mainly a JNK-dependent manner. Our findings highlight HRC as a potential therapeutic target for HCC treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.